IMMUNOISOLATED CELL TRANSPLANTS FOR TREATMENT OF PARKINSON'S DISEASE

Award Information
Agency:
Department of Health and Human Services
Branch
n/a
Amount:
$50,000.00
Award Year:
1990
Program:
SBIR
Phase:
Phase I
Contract:
n/a
Agency Tracking Number:
13992
Solicitation Year:
n/a
Solicitation Topic Code:
n/a
Solicitation Number:
n/a
Small Business Information
Cellular Transplants Inc
4 Richmond Sq, Providence, RI, 02906
Hubzone Owned:
N
Socially and Economically Disadvantaged:
N
Woman Owned:
N
Duns:
n/a
Principal Investigator:
Michael J Lysaght
(401) 272-3310
Business Contact:
() -
Research Institution:
n/a
Abstract
STRIATAL TRANSPLANTATION OF NEUROTRANSMITTER CELLS, IMMUNOISOLATED WITHIN A PERMSELECTIVE POLYMER MEMBRANE CAPSULE, REPRESENTS A NOVEL APPROACH TO THE TREATMENT OF PARKINSON'S DISEASE. THE TECHNIQUE HAS HAD PROMISING RESULTS IN SEVERAL RODENT MODELS, AND PRIMATE STUDIES ARE UNDERWAY. THE OVERALL OBJECTIVE OF THIS RESEARCH IS TO COMPLETE THE DEVELOPMENTS NECESSARY FOR WIDESPREAD MEDICAL ACCEPTANCE OF IMMUNOISOLATED CELLULAR TRANSPLANTATION IN THE TREATMENT OF NEURAL DISEASES. ONE UNACHIEVED PREREQUISITE TO SUCH ACCEPTANCE IS UNEQUIVOCAL DEMONSTRATION OF CAPSULE INTEGRITY AND COMPLETE SEGREGATION OF THE FOREIGN MATERIAL FROM THE HOST. ACCORDINGLY, THE SPECIFIC OBJECTIVE OF THIS PROJECT IS TO DEVELOP AND VALIDATE AN IN VIVO ASSAY OF INDIVIDUAL CAPSULE INTEGRITY BASED UPON ANTIBODY-MEDIATED COMPLEMENT LYSIS OF ENCAPSULATED PC12 CELLS.

* information listed above is at the time of submission.

Agency Micro-sites

US Flag An Official Website of the United States Government